NCCN adds revumenib to guidelines for NPM1-mutated leukemia

Syndax Pharmaceuticals (SNDX) has received a significant NCCN guideline update for its drug revumenib in relapsed/refractory NPM1-mutated AML, a common and underserved subtype, with an FDA Priority Review target action date of October 25, 2025. This development follows strong Q2 2025 financial results, where the company exceeded revenue and EPS forecasts, driven by robust sales growth for Revuforj (up 43% QoQ) and Niktimvo (up 166% QoQ). These positive commercial catalysts have prompted multiple analyst upgrades and price target increases, underscoring a favorable outlook for the biotech's trajectory.

Analysis

Syndax Pharmaceuticals (SNDX) is experiencing significant positive momentum driven by both clinical and commercial catalysts. The recent NCCN guideline update, including revumenib as a category 2A recommendation for NPM1-mutated AML, is a critical de-risking event ahead of a potential label expansion. This new indication targets a substantial patient population, as NPM1 mutations represent the most common genetic alteration in AML, occurring in approximately 30% of adult cases. The sNDA for this indication has received FDA Priority Review with a target action date of October 25, 2025, and is being reviewed under the Real-Time Oncology Review program, suggesting a favorable regulatory pathway. This clinical progress is supported by robust financial performance, as evidenced by the second-quarter 2025 results. The company significantly beat analyst expectations with revenue of $37.96 million versus a $27.13 million forecast, and a narrower loss per share of -$0.83 against a -$1.01 estimate. This outperformance was fueled by strong sequential sales growth from its key products: Revuforj revenue grew 43% to $28.6 million, and Niktimvo delivered $36.2 million, a 166% increase in its first full quarter. Consequently, multiple analysts have upgraded their outlook, with BTIG and Goldman Sachs raising price targets to $56.00 and $20.00 respectively, reflecting confidence in the company's commercial trajectory.

Key Decisions for Investors

• Investors should monitor the regulatory progress of revumenib's sNDA, as the recent NCCN guideline update is a strong positive leading indicator ahead of the October 25, 2025, FDA target action date.
• Evaluate the sustainability of the company's commercial execution, as continued quarter-over-quarter revenue growth for Revuforj and Niktimvo is critical to validating the bullish analyst price targets and supporting the stock's 17.76% six-month momentum.
• Acknowledge the high expectations set by multiple analyst upgrades and strong Q2 performance, while also considering the company's moderate debt levels against its strong liquidity position indicated by a current ratio of 4.71.